Postscripts from the post coronary artery bypass graft trial: The sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation

Circulation

Volumn 102, Issue 2, 2000, Pages 144-146

  Waters, David D ^a,b   Azar, Rabih R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Bypass; Editorials; Trials

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

ANTICOAGULATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY RISK; DATA ANALYSIS; EDITORIAL; HUMAN; HYPERLIPIDEMIA; MORTALITY; PRIORITY JOURNAL; RISK MANAGEMENT; SAPHENOUS VEIN GRAFT; TREATMENT OUTCOME;

EID: 0034636797     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.2.144     Document Type: Editorial

References (15)